Study of the Pharmacokinetics and Safety of Dioxidine®, Solution for Topical and External Use, 0.25 mg/ml, in Various Routes of Administration
Topical use of antibacterial drugs as part of complex therapy for purulent-inflammatory infections of the skin and oropharynx can not only eliminate the symptoms but also influence the cause of the disease. Dioxidine® is a broad-spectrum antibacterial drug, active against both gram-positive and gram...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC "Publishing House OKI"
2024-03-01
|
| Series: | Антибиотики и Химиотерапия |
| Subjects: | |
| Online Access: | https://www.antibiotics-chemotherapy.ru/jour/article/view/1096 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849244577907605504 |
|---|---|
| author | V. A. Stepanov S. V. Ponasenkova E. S. Simonova P. D. Sobolev A. G. Nikiforova A. A. Globenko A. V. Kapashin M. A. Pasko |
| author_facet | V. A. Stepanov S. V. Ponasenkova E. S. Simonova P. D. Sobolev A. G. Nikiforova A. A. Globenko A. V. Kapashin M. A. Pasko |
| author_sort | V. A. Stepanov |
| collection | DOAJ |
| description | Topical use of antibacterial drugs as part of complex therapy for purulent-inflammatory infections of the skin and oropharynx can not only eliminate the symptoms but also influence the cause of the disease. Dioxidine® is a broad-spectrum antibacterial drug, active against both gram-positive and gram-negative bacteria. The aim of this study was to investigate the bioavailability, pharmacokinetic parameters, and safety profile of Dioxidine®, solution for topical and external use, 0.25 mg/ml, in cutaneous and topical application. Another dosage form of Dioxidine® — a solution for infusion and external use, 5 mg/ml — was used as a comparison drug. The study consisted of 4 stages reflecting different routes of drug administration: rinsing the oropharynx (path A), a single irrigation of the oropharynx using a spray nozzle (path B), back skin irrigation (path C), and intravenous administration (path D — for the reference drug). The results of the study made it possible to determine the absolute dose-normalized bioavailability of the study drug in the indicated routes of administration, as well as to evaluate its safety profile. |
| format | Article |
| id | doaj-art-02815f12c2154f779faed4f23c8b22a8 |
| institution | Kabale University |
| issn | 0235-2990 |
| language | Russian |
| publishDate | 2024-03-01 |
| publisher | LLC "Publishing House OKI" |
| record_format | Article |
| series | Антибиотики и Химиотерапия |
| spelling | doaj-art-02815f12c2154f779faed4f23c8b22a82025-08-20T03:59:08ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902024-03-016811-12303710.37489/0235-2990-2023-68-11-12-30-371005Study of the Pharmacokinetics and Safety of Dioxidine®, Solution for Topical and External Use, 0.25 mg/ml, in Various Routes of AdministrationV. A. Stepanov0S. V. Ponasenkova1E. S. Simonova2P. D. Sobolev3A. G. Nikiforova4A. A. Globenko5A. V. Kapashin6M. A. Pasko7X7 Clinical Research, LLCX7 Clinical Research, LLCX7 Clinical Research, LLCExacte Labs, LLCExacte Labs, LLCValenta Pharm JSCValenta Pharm JSCValenta Pharm JSCTopical use of antibacterial drugs as part of complex therapy for purulent-inflammatory infections of the skin and oropharynx can not only eliminate the symptoms but also influence the cause of the disease. Dioxidine® is a broad-spectrum antibacterial drug, active against both gram-positive and gram-negative bacteria. The aim of this study was to investigate the bioavailability, pharmacokinetic parameters, and safety profile of Dioxidine®, solution for topical and external use, 0.25 mg/ml, in cutaneous and topical application. Another dosage form of Dioxidine® — a solution for infusion and external use, 5 mg/ml — was used as a comparison drug. The study consisted of 4 stages reflecting different routes of drug administration: rinsing the oropharynx (path A), a single irrigation of the oropharynx using a spray nozzle (path B), back skin irrigation (path C), and intravenous administration (path D — for the reference drug). The results of the study made it possible to determine the absolute dose-normalized bioavailability of the study drug in the indicated routes of administration, as well as to evaluate its safety profile.https://www.antibiotics-chemotherapy.ru/jour/article/view/1096dioxidine®hydroxymethylquinoxalindioxidepharmacokineticsbioavailabilitysafetyacute tonsillopharyngitispyoderma |
| spellingShingle | V. A. Stepanov S. V. Ponasenkova E. S. Simonova P. D. Sobolev A. G. Nikiforova A. A. Globenko A. V. Kapashin M. A. Pasko Study of the Pharmacokinetics and Safety of Dioxidine®, Solution for Topical and External Use, 0.25 mg/ml, in Various Routes of Administration Антибиотики и Химиотерапия dioxidine® hydroxymethylquinoxalindioxide pharmacokinetics bioavailability safety acute tonsillopharyngitis pyoderma |
| title | Study of the Pharmacokinetics and Safety of Dioxidine®, Solution for Topical and External Use, 0.25 mg/ml, in Various Routes of Administration |
| title_full | Study of the Pharmacokinetics and Safety of Dioxidine®, Solution for Topical and External Use, 0.25 mg/ml, in Various Routes of Administration |
| title_fullStr | Study of the Pharmacokinetics and Safety of Dioxidine®, Solution for Topical and External Use, 0.25 mg/ml, in Various Routes of Administration |
| title_full_unstemmed | Study of the Pharmacokinetics and Safety of Dioxidine®, Solution for Topical and External Use, 0.25 mg/ml, in Various Routes of Administration |
| title_short | Study of the Pharmacokinetics and Safety of Dioxidine®, Solution for Topical and External Use, 0.25 mg/ml, in Various Routes of Administration |
| title_sort | study of the pharmacokinetics and safety of dioxidine r solution for topical and external use 0 25 mg ml in various routes of administration |
| topic | dioxidine® hydroxymethylquinoxalindioxide pharmacokinetics bioavailability safety acute tonsillopharyngitis pyoderma |
| url | https://www.antibiotics-chemotherapy.ru/jour/article/view/1096 |
| work_keys_str_mv | AT vastepanov studyofthepharmacokineticsandsafetyofdioxidinesolutionfortopicalandexternaluse025mgmlinvariousroutesofadministration AT svponasenkova studyofthepharmacokineticsandsafetyofdioxidinesolutionfortopicalandexternaluse025mgmlinvariousroutesofadministration AT essimonova studyofthepharmacokineticsandsafetyofdioxidinesolutionfortopicalandexternaluse025mgmlinvariousroutesofadministration AT pdsobolev studyofthepharmacokineticsandsafetyofdioxidinesolutionfortopicalandexternaluse025mgmlinvariousroutesofadministration AT agnikiforova studyofthepharmacokineticsandsafetyofdioxidinesolutionfortopicalandexternaluse025mgmlinvariousroutesofadministration AT aaglobenko studyofthepharmacokineticsandsafetyofdioxidinesolutionfortopicalandexternaluse025mgmlinvariousroutesofadministration AT avkapashin studyofthepharmacokineticsandsafetyofdioxidinesolutionfortopicalandexternaluse025mgmlinvariousroutesofadministration AT mapasko studyofthepharmacokineticsandsafetyofdioxidinesolutionfortopicalandexternaluse025mgmlinvariousroutesofadministration |